Global Success Review Magazine | News Desk | May 27, 2025
In a bold display of investor confidence and sector resilience, Quadria Capital, one of Asia’s leading healthcare-focused private equity firms, has successfully closed its third healthcare fund, securing $1.07 billion in total commitments. This significant milestone not only surpasses the firm’s original $800 million target but also reinforces Quadria’s position as the largest dedicated healthcare private equity player in South and Southeast Asia.
Despite a backdrop of global fundraising headwinds, Fund III was oversubscribed, drawing $954 million in primary capital and an additional $114 million in committed co-investment funds. The firm also anticipates a further $300 million in co-investment capacity throughout the investment cycle—bringing the total capital pool to approximately $1.3 billion when fully deployed.
This third fund is approximately 60% larger than its 2020 predecessor, signaling strong momentum for Quadria’s strategy of backing healthcare enterprises that deliver both measurable social impact and robust financial returns.
“Fund III’s close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission,” said Abrar Mir, Co-Founder and Managing Partner at Quadria Capital. “It reflects deep global investor conviction in the transformational opportunity in Asian healthcare, where social impact and financial performance go hand in hand.”
A Diverse and Committed Investor Base
Quadria attracted support from a broad spectrum of investors, including sovereign wealth funds, global asset managers, and strategic corporates across North America, Europe, and the Gulf. Notably, participation from institutional and family office investors in Asia continues to rise.
The firm also recorded a significant increase in loyalty from its existing investor base, with previous backers upping their commitments by an average of 80%, reflecting enduring confidence in Quadria’s impact-led investment thesis.
Strategic Focus and Deployment
Nearly 40% of the fund has already been deployed into companies such as Aragen Life Sciences, NephroPlus, and Maxivision. Two additional transactions in Southeast Asia are reportedly in the final stages of closing.
Quadria’s investment focus remains aligned with high-growth, high-impact segments such as specialty hospitals, diagnostics, medtech, and pharmaceutical manufacturing, particularly in India and Southeast Asia. With the Asian continent expected to account for 40% of global healthcare growth by 2030, the firm aims to scale a portfolio of around 10 market-leading companies, leveraging both majority and significant minority stakes, along with strategic co-investments.
A Vision for Scalable Healthcare Impact
Quadria’s approach continues to blend financial discipline with a mission to deliver affordable, accessible, and quality healthcare to underserved communities across emerging Asia. As global investors increasingly gravitate toward resilient and socially responsible sectors, Quadria Capital’s latest fund close reaffirms its role as a pivotal force in shaping the future of healthcare investment in the region.
Stay tuned to Global Success Review Magazine for more insights into the world’s most impactful investment strategies and the firms redefining business with purpose.
